Hope Rugo, MD, director of the breast oncology clinical trials program at the University of California at San Francisco, discusses advances in the treatment of HER2-positive breast cancer.
Transcript:
Is there anything you’re working on or excited about in HER2-positive breast cancer that you’d like to share?
We're working on a number of different things. One is trying to move neratinib earlier in the adjuvant course and seeing if we can manage the diarrhea with a novel agent. So that’s one trial my colleague Joe Chen is working on.
In terms of the metastatic setting, there are a number of novel agents, oral TKIs [tyrosine-kinase inhibitors], and then an antibody—drug conjugate from Daiichi which has shown responses in patients who had highly resistant disease, at least as reported to trastuzumab. That’s going into a phase 3 trial this year. Then there’s a novel antibody that binds to the receptors a bit differently called margetuximab that’s in a phase 3 trial called the SOPHIA trial. That drug also showed responses in phase 1 studies in patients who had disease resistant to trastuzumab.
So, I think there’s a number of different agents out there which seem as though they have potential for the future.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.